FEBO-G Tablet

ក្រុមហ៊ុនផលិតឱសថ:

 

Getz pharma, USA

  • សារធាតុសកម្ម
  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
  • ហាមប្រើ
  • ផលរំខាន
  • អន្តរប្រតិកម្ម
  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន
  • ការប្រុងប្រយ័ត្នជាពិសេស
  • សកម្មភាពឱសថ
  • បរិយាយប័ណ្ណឱសថ 
  • សារធាតុសកម្ម

    1. FEBO-G Tablets 40mg:

    Febuxostat 40mg

    1. FEBO-G Tablets 80mg:

    Febuxostat 80mg

  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់

    For the chronic management of hyperuricemia in patients with gout.

     

    Dosage and administration

    For treatment of hyperuricemia in patients with gout.

    40-80mg once daily.

    The recommended starting dose is 40mg once daily. For patients who do not achieve a serum uric acid less than 6mg/dL after 2 weeks with 40mg, Febo-G 80mg is recommended.

    Febo-G can be taken without regard to food or antacid use.

     

    See the package insert about the details below:

    - Renal insufficiency

    - Hepatic insufficiency

  • ហាមប្រើ

    - Hypersensitivity to the active substance or to any of the excipients.

    - Being treated with azathioprine, mercaptopurine, or theophylline.

    - Asymptomatic hyperuricemia.

  • ផលរំខាន

    Common

    Headache, Diarrhea, Nausea, Rash, LFT Abnormalities.

    Uncommon

    Blood amylase increase, platelet count decrease, blood creatinine increase, hemoglobin decrease, blood urea increase, LDH increase, triglycerides increase, dizziness, paraesthesia, somnolence, altered taste, abdominal pain, gastro-oesophageal reflux disease, vomiting, dry mouth, dyspepsia, constipation, frequent stools, flatulence, gastrointestinal discomfort, nephrolithiasis, hematuria, pollakisuria, dermatitis, urticaria, pruritus, arthralgia, arthritis, myalgia, muscle cramp, musculoskeletal pain, weight increase, increased appetite, hypertension, flushing, hot flush, fatigue, edema, influenza like symptoms, libido decreased.

    Rare

    Palpitations, renal insufficiency, asthenia, thirst, nervousness, insomnia.

  • អន្តរប្រតិកម្ម

    See the package insert about the details below:

    - Naproxen and other inhibitors of glucuronidation

    - Inducers of glucuronidation

  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន

    Should not be usd.

  • ការប្រុងប្រយ័ត្នជាពិសេស

    - Treatment with febuxostat in patients with ischemic heart disease or congestive heart failure is not recommended.

    - After initiation of febuxostat, an increase in gout flares is frequently observed. This increase is due to reduction in serum uric acid levels resulting in mobilization of urate from tissue deposits. In order to prevent gout flares when febuxostat is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended.

    - As with other urate lowering medicinal products, in patients in whom the rate of urate formation is greatly increased (e.g. malignant disease and its treatment, Lesch-Nyhan syndrome) the absolute concentration of xanthine in urine could, in the urinary tract. As there has been no experience with febuxostat, its use in these populations is not recommended.

    - Laboratory assessment of liver function is recommended at, for example 2-4 months following initiation of febuxostat and periodically thereafter.

  • សកម្មភាពឱសថ

    Febuxostat is a potent, non-purine, selective inhibitor of xanthine oxidase that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting xanthine oxidase. Uric acid is the end product of purine metabolism and is generated in the cascade of hypoxanthine→xanthine→furic acid. Both steps in the transformation are catalyzed by xanthine oxidase. At therapeutic concentrations febuxostat does not inhibit other enzymes involved in purine or pyrimidine metabolism, namely, guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate phosphoribosyltransferase, orotidine monophosphate phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine nucleoside phosphorylase.

*ព័ត៌មានឱសថត្រូវបានរៀបរៀងដោយ អ៊ីម៉ាតុគឹ មេឌីក (ខេមបូឌា) ដោយផ្អែកលើប្រភពព័ត៌មានខាងក្រោម។ សម្រាប់ព័ត៌មានលម្អិត សូមស្វែងរកនៅក្នុងក្រដាសព័ត៌មាននៃឱសថនីមួយៗ ឬ សាកសួរទៅកាន់ក្រុមហ៊ុនឱសថឬតំណាងចែកចាយនៃឱសថនីមួយៗ។

ប្រភពព័ត៌មាន៖

- ក្រដាសព័ត៌មាននៃឱសថសម្រាប់អ្នកជំនាញវេជ្ជសាស្ត្រដែលប្រើប្រាស់នៅប្រទេសជប៉ុន (Pharmaceutical and Medical Devices Agency, Pmda): https://www.pmda.go.jp

- ព័ត៌មានសង្ខេបនៃឱសថសម្រាប់អ្នកជំងឺដែលប្រើប្រាស់នៅប្រទេសជប៉ុន: http://www.rad-ar.or.jp